Morphological characteristics of recurrent papillary thyroid carcinoma

Close metadata

Recommended articles:

Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology. 2024;(2):39-45

Dacryocystorhinostomy with a counteropening in the treatment of secondary nasolacrimal duct obstruction after radioiodine therapy. Russian Annals of Ophthalmology. 2024;(2-2):60-67

Pharmacological prevention of fibrosis in dacryosurgery. Russian Annals of Ophthalmology. 2024;(2-2):180-189

The results of clinical application of the mesh with anti-adhesive fluoropolymer coating in laparoscopic intraperitoneal repair of primary ventral hernia. Pirogov Russian Journal of Surgery. 2024;(5):86-94

Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):90-96

Epidemiological features of laryngeal papillomatosis in adults in Moscow. Russian Bulletin of Otorhinolaryngology. 2024;(3):4-10

Trouble issues of acne therapy with systemic isotretinoin. Russian Journal of Clinical Dermatology and Venereology. 2024;(4):459-466

Prediction of papillary thyroid cancer recurrence according to preoperative data. Pirogov Russian Journal of Surgery. 2024;(9):76-85

Disease-free survival after surgical and combined treatment of newly diagnosed craniopharyngiomas in adults. Burdenko's Journal of Neurosurgery. 2024;(5):54-59

Surgical treatment of perianal abscess and fistula-in-ano in neonates and infants. Pirogov Russian Journal of Surgery. 2024;(11):46-53

Papillary thyroid carcinoma is generally characterized by a favorable prognosis in patients after timely and adequate treatment. However, local tumor growth recurrences and regional and distant metastases may occur in 5-20% of cases posttreatment. Objective - to comparatively analyze the morphology and cellular composition of papillary thyroid carcinoma in two patient groups with comparable clinical and morphological characteristics, but different in the long-term results of treatment. Material and methods. Histological specimens from 17 papillary thyroid carcinoma cases with recurrent tumor growth after treatment and resurgery (an experimental group) and 18 control cases without recurrences were selected from the database of the Chernobyl bank. The morphological features of primary tumors were studied in both groups; the morphology of recurrent tumors was also investigated in the experimental group. Results. The higher incidence of tumors with papillary structure and a focal component from high-columnar, clear, and oxyphilic tumor cells was found in a group with a poor prognosis (a local relapse and metastases in the regional lymph nodes after thyroidectomy, hormonal and radioiodine therapy. Conclusion. The found morphological features of recurrent papillary thyroid carcinoma may serve as a starting point for further establishing criteria for tumor resistance to radioiodine therapy and for substantiating indications for other high-technology treatments, including targeted therapy.

Keywords:

papillary thyroid carcinoma

recurrence

radioiodine therapy

Authors:

Abrosimov A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Ryzhenkova M.I.

Hertsen Federal Medical Research Centre, Obninsk, Russia

List of references:

Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19 (11): 1167-214.
Tala H., Tuttle R.M. Contemporary post surgical management of differentiated thyroid carcinoma. Clin. Oncol. 2010; 22 (6): 419-29.
Wong K.-P., Lang B. H.-H. New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J. Thyroid Res. 2012: doi: 10.1155/2012/818204.
Capdevila J., Argiles G., Rodriguez-Frexinos V., Nunez I., Tabernero J. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov. Med. 2010; 9 (45): 153-62.
Duntas L.H., Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid. 2010; 20 (12): 1351-8.
Chen L., Shen Y., Luo Q., Yu Y., Lu H., Zhu R. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid. 2011; 21 (2): 119-24.
Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J. Endocrinol. Invest. 2012; 35 (6, Suppl.): 40-4.
Shinkarkina A.P., Abrosimov A.Yu., Lushnikov E.F., Konova M.V., Petukhova N.S., Stepanenko V.F. et al. International project "Chernobyl Tissue Bank": results and perspectives for study of radiation-induced thyroid pathology. Meditsinskaya radiologiya i radiatsionnaya bezopasnost'. 2011; 56 (6): 30-41. (In Russ.)
DeGroot L.J., Kaplan E.L., McCormick M. et al. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Matab. 1990; 71 (2): 414-24.
Miyauchi A., Kudo T., Kihara M., Higashiyama T., Ito Y., Kobayashi K., Miya A. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocrinol. J. 2013; 60 (4): 415-21.
Lang B.N., Lee G.C., Ng C.P., Wong K.P., Wan K.Y., Lo C.Y. Evaluating the morbidity and efficacy of preoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma. World J. Surg. 2013; 37 (12): 2853-9.
Abrosimov A.Yu., Kozhushnaya S.M. Morphological features of papillary thyroid cancer with focal high-cellular component. Arkhiv patologii. 2012; 74 (4): 38-42. (In Russ.)
Abrosimov A.Yu., Kozhushnaya S.M. Papillary thyroid cancer of high and columnar cells. Arkhiv patologii. 2011; 73 (2): 50-54. (In Russ.)
Asioli S., Erickson L.A., Sebo T.J., Zhang J., Jin L., Thompson G.B. et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am. J. Surg. Pathol. 2010; 34 (1): 44-52.
Dettmer M., Schmitt A., Steinert H., Moch H., Komminoth P., Perren A. Poorly differentiated oncocytic carcinoma - diagnostic implications and outcome. Histopathology. 2012; 60 (7): 1045-51.
Abrosimov A.Yu., Berdov B.A., Erygin D.V., Kondrashova L.M., Lushnikov E.F., Nevol'skikh A.A. Pathomorphosis of rectal cancer with neoadjuvant chemoradiotherapy. Arkhiv patologii. 2013; 75 (6): 27-31. (In Russ.)
Durante C., Tallini G., Puxeddu E., Sponziello M., Moretti S., Ligorio C. et al. BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur. J. Endocrinol. 2011; 165 (3): 455-63.
Chakravarty D., Santos E., Ryder M., Knauf J.A., Liao X.-H., West B.L. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 2013; 121 (12): 4700-11.

Close metadata